← Oncology Approval Tracker

FDA DECISION ·

Zynyz

retifanlimab-dlwr · Incyte

FDA approvalNew or expanded indicationAnal canal squamous cell carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

As a single agent for adults with locally recurrent or metastatic anal canal squamous cell carcinoma whose disease progressed on platinum-based chemotherapy or who could not tolerate it.

LAMPGEN ANALYSIS

Why it matters

The monotherapy label addresses a post-platinum or platinum-intolerant population distinct from the first-line combination.

What research teams should watch

Capture whether treatment stopped because of progression or intolerance, and use the appropriate criterion during prescreening.

PRIMARY RECORDS

Sources